Search
Showing results for "1"
Find out how to participate in our research and community groups.
Find out more about the activities and highlights of ORIGINS.
Research
Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemiaSensor-augmented insulin pump with automated low-glucose insulin suspension has the potential to reduce the incidence of major hypoglycemic events.
Research
Immune modulation by UV: Role of vitamin DIn this chapter, evidence for and evidence against the involvement of vitamin D in the immunoregulatory properties of UV radiation is presented.
Research
Continuous Glucose Monitoring Adherence: Lessons from a Clinical Trial to Predict Outpatient BehaviorContinuous glucose monitoring adherence and patterns of use are individualized
Research
Maternal Work–Family Conflict and Psychological Distress: Reciprocal Relationships Over 8 YearsEmployed mothers may benefit from policies and workplace practices that promote maternal well-being and reduce conflicts between employment and raising children
Research
Individual-Level Risk and Resilience Factors Associated with Mental Health in Siblings of Individuals with Neurodevelopmental Conditions: A Network AnalysisSiblings of individuals with neurodevelopmental conditions (NDCs) are exposed to unique family environments and experience a range of psychosocial risk and resilience factors.
News & Events
Research Intern SpotlightAlice Lafana is one of our Research Interns who is currently studying her Masters of Public Health at the University of WA, and interning with the Mental Health team.
Research
“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trialsEach year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.
Research
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic LeukemiaKMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.